STRIDES PHARMA SCIENCE LIMITED — Board/Management Information 2020

Jan 8, 2020

January 8, 2020

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited Exchange Plaza , Bandra-Kurla Complex Bandra (E) Mumbai - 400 051

Scrip code: 532531 Scrip code: STAR

Dear Sirs,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

“Dr. R Ananthanarayanan appointed as the new CEO & Managing Director of Strides”

Thanks & Regards,

For Strides Pharma Science Limited Manjula Ramamurthy Company Secretary

Strides Pharma Science Limited

(Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 info@strides.com; www.strides.com

Press Release January 08, 2020

==> picture [106 x 41] intentionally omitted <==

Dr. R Ananthanarayanan appointed as the new CEO & Managing Director of Strides

Bangalore, January 08,2020 – Strides Pharma Science Limited (Strides) today announced that the Board of Directors (Board) of the Company have appointed Dr. R Ananthanarayanan as Chief Executive Officer (CEO) and Managing Director (MD) of Strides effective January 09, 2020.

Dr. R Ananthanarayanan (Ananth) will succeed Arun Kumar, Founder, and the incumbent CEO & MD of the Company. Arun will transition his active responsibilities at Strides by the financial year ending March 31, 2020, and will step into a strategic role as Chairman of the Board with effect from April 01, 2020.

Ananth brings with him over three decades of top pedigree global pharmaceutical experience across both the technical and commercial functions. Until recently, Ananth was the Global Chief Operating Officer at Cipla Limited, where he was responsible for the company’s generics business in regulated markets and branded generics in emerging markets. He was also driving their API business, biosimilars, complex drug-device combinations, including 505(b)(2) products.

Prior to Cipla, Ananth was the President & CEO of Global APIs, Biologics, & Medis Generics B2B division at Teva Pharmaceutical Industries Ltd in the US, managing multi-billion P&L responsibility. He has also held leadership roles at Dr. Reddy’s Laboratories, Piramal Healthcare (Formerly Nicholas Piramal), Galpharm International, UK (Acquired by Perrigo Group), and Zydus Cadila.

Ananth is a Graduate in Pharmaceutical Sciences and earned his Ph.D. in Pharmaceutical Technology from the University of Mumbai, India. He has also been a member of the Board of Advisors at the School of Pharmacy and Health Sciences at Fairleigh Dickinson University, New Jersey.

Ananth’s appointment at Strides comes at the time when the company has concluded its reset strategy to drive profitable future growth on the back of a stronger balance sheet. The Board strongly believes that Ananth’s exceptional global techno-commercial experience and leadership stature in managing the P&Ls of large global pharmaceutical companies will multiply the company’s commitment to creating perpetual value for all its stakeholders.

Expressing confidence in the Board’s choice , Arun Kumar, remarked, “Having founded Strides and led the company for close to 30 years, I believe the time is right for me to step aside and have Ananth lead it to greater heights. Ananth brings in the right balance of technical and commercial expertise, and I am confident that Strides will significantly benefit from his leadership experience, industry perspective, technical knowledge, and business acumen. As he takes on the mantle of Strides, I will now move to a more strategic role as the Chairman of the

Board and will dedicate time to Strides' newly announced investments in Biotech and sterile injectables.”

Dr. R Ananthanarayanan, the new CEO & MD of Strides, commented, “It's my privilege and honor to take over as the CEO &MD of Strides, and I would like to appreciate the confidence reposed in me by Arun and the Board. These are exciting times for Strides, and I look forward to partner with all the global colleagues to ensure successful realization of the Strides strategic objectives while ensuring that we consistently deliver quality medicines to all our patients globally.”

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi, and United States-Florida. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

StridesBadree KomandurExecutive Director - Finance+91 80 6784 0747Investor Relations:Kannan. N:+91 98450 54745Vikesh Kumar:+91 80 6784 0827Sandeep Baid:+91 80 6784 0791Email:Sandeep.baid@strides.comStrides Pharma Science Limited(Formerly Strides Shasun Limited)CIN: L24230MH1990PLC057062Regd. Office: 201, ‘Devavrata’, Sector - 17,Vashi, Navi Mumbai - 400 703Corp. Office: Strides House, BannerghattaRoad,Bangalore – 560 076		PR ConsultancyFortuna PRK Srinivas Reddy: +91 90005 27213srinivas@fortunapr.com K Priya: +91 95354 25418priya@fortunapr.com